Dallas, TX (PRWEB) October 24, 2012
A report issued by the Institute for Safe Medicine Practices’ QuarterWatch (PDF) on October 3, 2012 estimates that prescription drug complaints to the FDA have risen 90% in the past 4 years, and two drugs, Pradaxa and Chantix, are responsible for 37% of that increase.
The report comes as The Journal for The American Medical Association last month warned that the FDA may have rushed approval of the drug Pradaxa, overlooking key Pradaxa side effects like internal bleeding.
Now that federal Judge David Herndon has issued an order on July 24th that victims can proceed with lawsuits, anyone affected by internal bleeding after taking Pradaxa is urged to learn about their legal options as soon as possible.
The FDA warned on December 7, 2011 that it was investigating Pradaxa after receiving more injury or death reports than expected. USA Today reported on August 19th that the FDA received 3,781 reports of side effects and 542 deaths among Pradaxa users last year, leading all other medications in 2011.
Due to the number of Pradaxa claims expected, a central court was recently established in Illinois to handle the lawsuits. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. On September 5, 2012, the United States Judicial Panel on Multidistrict Litigation indicated more than 100 Pradaxa claims have now been filed.
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.